For the fifth year, Redeye will host an event on the topic of drug development in neurology/diseases of the brain.

 

This year, we will specifically focus on three major indications: Pain, Parkinson’s disease and Alzheimer’s disease.

 

One of the topics will be the recent success with BioArctic’s drug candidate Lecanemab, which could possibly become the first fully approved disease-modifying treatment for Alzheimer’s, and its potential impact on the sector as a whole.

 

NOTE!

Companies and schedules may change before the event starts.

You can save the date in your calendar by using Add to calendar.